Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.

De Castro N, Marcy O, Chazallon C, Messou E, Eholié S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B, ANRS 12300 Reflate TB2 study group

Open source

DOI: 10.1016/s1473-3099(20)30869-0
Published: 2021 Jun
Container: The Lancet. Infectious diseases
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-20-30869-0,
  title = {Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.},
  author = {De Castro N and Marcy O and Chazallon C and Messou E and Eholié S and N'takpe JB and Bhatt N and Khosa C and Timana Massango I and Laureillard D and Chau GD and Domergue A and Veloso V and Escada R and Wagner Cardoso S and Delaugerre C and Anglaret X and Molina JM and Grinsztejn B and ANRS 12300 Reflate TB2 study group},
  year = {2021},
  journal = {The Lancet. Infectious diseases},
  doi = {10.1016/s1473-3099(20)30869-0},
  url = {https://doi.org/10.1016/s1473-3099(20)30869-0}
}

RIS

TY  - JOUR
TI  - Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
AU  - De Castro N
AU  - Marcy O
AU  - Chazallon C
AU  - Messou E
AU  - Eholié S
AU  - N'takpe JB
AU  - Bhatt N
AU  - Khosa C
AU  - Timana Massango I
AU  - Laureillard D
AU  - Chau GD
AU  - Domergue A
AU  - Veloso V
AU  - Escada R
AU  - Wagner Cardoso S
AU  - Delaugerre C
AU  - Anglaret X
AU  - Molina JM
AU  - Grinsztejn B
AU  - ANRS 12300 Reflate TB2 study group
PY  - 2021
JO  - The Lancet. Infectious diseases
DO  - 10.1016/s1473-3099(20)30869-0
UR  - https://doi.org/10.1016/s1473-3099(20)30869-0
ER  -

APA

N, D. C., O, M., C, C., E, M., S, E., JB, N., N, B., C, K., I, T. M., D, L., GD, C., A, D., V, V., R, E., S, W. C., C, D., X, A., JM, M., B, G., & group, A. 1. R. T. S. (2021). Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.. The Lancet. Infectious diseases. https://doi.org/10.1016/s1473-3099(20)30869-0

Source records

pubmed · retrieved 2026-09-27T08:37:55.687Z